Tolerability and Persistence with Subcutaneous Immunoglobulin Provided Through Physician Clinics for the Treatment of Primary Immunodeficiencies

Presented on February 22, 2019

Richard F. Herrscher, MD, FACAAI – AIRCare, Dallas, TX
Tidence L. Prince, MD – The Allergy Asthma and Sinus Center, Knoxville
Lucinda J. Van Anglen, PharmD – Healix Infusion Therapy, Sugar Land, TX
Claudia P. Schroeder, PharmD, PhD – Healix Infusion Therapy, Sugar Land, TX

View Poster

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.